Hichi Development

Founded in 2006, the company is located in Taizhou City, Zhejiang Province, the most dynamic chemical API manufacture base in southeastern China.

Engaged in the production and sales of APIs like X-CT non-ionic iodine contrast agents, Hichi has obtained a number of invention patents. We has passed the CFDA’s GMP certification for APIs, as well as certifications such as ISO9001 quality management system, ISO14001 environmental system, and OHSAS18001 Occupational Health and Safety Assessment Series.

2006

ZHEJIANG HICHI PHARMACEUTICAL CORPORATION LIMITED was established

2006

In November, 2006, the pre-evaluation safety report of “GMP technical transformation project of 60 tons/year iodine contrast agent pharmaceutical raw material drug ” passed the review of the expert review team.

2009

In 2009, Obtained the registration certificate of iohexol. In April of the same year, Hichi Pharmaceutical signed an agreement with Xiamen University to carry out technical research and development cooperation on the production technology of iopromide, a contrast-enhancing agent (contrast agent) for medical CT.

2010

In April, 2010 Hichi Pharmaceutical obtained GB/T 19001-2008/ISO 9001: 2008 quality management system certification.

2015

In November, 2015, the company Hichi Pharmaceutical successfully landed on the New Third Board. (Stock code 834402)

2016

In October, 2016, Hichi purchased 75 acres of land and settled in Shamen Bingang Industrial City.

2018

In 2018, Beilu Pharmaceutical takes a stake in Hichi Pharmaceutical

2020

In July, 2020, the company’s annual output of 850 tons of iodine contrast agent production line technical transformation project was put into trial production.

2021

In March, 2021, the company passed the GMP audit, and in July passed the safety and environmental protection completion acceptance and obtained the safety production license.

2021

In 2021, Received capital injection from Beijing Telford Assets in November